118th CONGRESS 2d Session |
To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
This Act may be cited as the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023”.
SEC. 2. Reauthorization of sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment.
Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—
(1) in paragraph (3)(A), by inserting “, grant, or cooperative agreement” after “contract”; and
(2) in paragraph (6), by striking “$4,455,000 for each of fiscal years 2019 through 2023” and inserting “$8,205,000 for each of fiscal years 2024 through 2028”.
Passed the House of Representatives September 23, 2024.
Attest:
Clerk.
| |||||
AN ACT | |||||
To amend title XI of the Public Health Service Act to reauthorize the program providing for sickle cell disease and other heritable blood disorders research, surveillance, prevention, and treatment. |